# Hypofractionated IMRT With Concurrent Chemotherapy in Muscle-invasive Bladder Cancer (HIRACUM)

> **NCT05453682** · NA · RECRUITING · sponsor: **Samsung Medical Center** · enrollment: 53 (estimated)

## Conditions studied

- Bladder Cancer

## Interventions

- **RADIATION:** hypo-IMRT

## Key facts

- **NCT ID:** NCT05453682
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-14
- **Primary completion:** 2026-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2024-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05453682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05453682, "Hypofractionated IMRT With Concurrent Chemotherapy in Muscle-invasive Bladder Cancer (HIRACUM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05453682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*